Palisades Therapeutics Announces New Anti-Cancer Drug-PT162, a p53-Reactivating Cell Cycle Checkpoint Inhibitor
Newly Patented PT162 Induces Cancer Cell Cycle Arrest and/or Apoptosis by Restoring DNA-Binding Activity of Mutant p53 Protein CLIFFSIDE PARK, NJ, UNITED STATES, January 3, 2023 /EINPresswire.com/ -- One of the most common genetic changes resulting in …